Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Bethesda, Maryland 20892


This study will try to identify and treat feeder vessels in age-related macular degeneration. The macula is the part of the retina in the back of the eye that determines central or best vision. In macular degeneration, leaking blood vessels under the macula lead to loss of central vision. These vessels branch out tree-like from one or more feeder vessels. Instead of treating all the abnormal branching vessels, this study will try to find and close only the feeder vessels, thereby depriving the abnormal vessels of nutrition. The vessels will be closed with laser beam treatment. People 50 years of age and older with macular degeneration and visual acuity worse than 20/50 in the study eye and the same or better vision in the other eye may be eligible for this study. Candidates will undergo fluorescein angiography to try to locate feeder vessels. For this procedure, a yellow dye is injected into an arm vein. The dye travels to the blood vessels in the eyes, and pictures of the retina are taken using a camera that flashes a blue light into the eye. The pictures show if any dye has leaked from the vessels into the retina, indicating possible blood vessel abnormality. Before laser treatment, participants will have a complete eye examination, including measurement of visual acuity, evaluation of the front part of the eye with a slit lamp microscope, examination of the retina with an ophthalmoscope, and measurement of eye pressure using a tonometer. During the laser treatment phase of the study, participants will have indocyanine green angiography-a procedure similar to fluorescein angiography, but using a green dye-to photograph the retina and identify feeder vessels. If feeder vessels are located, laser beam treatment will begin. For this procedure, the eye is anesthetized with numbing drops. A special contact lens is then placed on the eye for the laser treatment. The number of treatments depends on how well the individual patient responds, but usually between two and eight treatments are required. The indocyanine green angiogram will be repeated after the laser beam treatment to determine if the feeder vessels have been successfully closed. If the vessels remain partially open, a repeat application will be done, followed by another indocyanine green angiogram to check the results. Patients will be checked in the clinic after 1 week to see if additional treatment is needed. If so, re-treatment will be done in a week. If no re-treatment is required, follow-up visits will be scheduled 2, 3, and 6 weeks after treatment, 3 and 6 months after treatment, and every 6 months after that for 2 years to evaluate treatment results. The evaluations will include fluorescein angiograms and other examinations that were done before starting treatment. If abnormal vessels are still present or growing, repeat treatments will be applied following the same procedure.

Study summary:

Age-related macular degeneration (AMD) represents the most common cause of blindness in patients over the age of 60. Most vision loss in this disease results from sequelae of choroidal neovascular membrane (CNVM) formation. CNVM is usually composed of well-formed neovascularization and occult (less well-formed) neovascularization. While clinical trials have shown that some patients, mostly those with well-formed CNVM, may benefit from laser photocoagulation or photodynamic therapy, at present there is no treatment for patients who have combined CNVM lesions (both well-formed and occult) whose area of occult neovascularization is greater than 50% or who have other presentation of CNVM such as pigment-epithelial detachment or neovascular fibrosis. Retinal histopathology of patients with choroidal neovascularization has revealed that areas of CNVM are usually fed by a few smaller choroidal feeder vessels originating from the choroid or choriocapillaris. Therefore, it has been hypothesized that closure of these feeder vessels would infarct the large CNVM complex. Until recently, identification of these feeder vessels has been difficult but new high speed indocyanine imaging of the choroid (Phi-motion) indocyanine green angiography (ICG) has allowed for more precise detection of these vessels. We will test this hypothesis by utilizing Phi-motion ICG to identify choroidal feeder vessels in patients with CNVM not amenable to approved treatments. If feeder vessels are identified, then pulse-diode laser photocoagulation will be used to attempt closure of these vessels. The study is designed to provide information on the feasibility of standardizing this procedure and estimating its potential efficacy. The primary outcome will be a greater than 50% reduction in the area of leakage from the neovascular component as determined by fluorescein angiogram. Secondary outcomes will include a complete resolution of leakage measured by fluorescein angiography, the number of repetitive laser treatments undergone, the number of patients eligible by fluorescein angiogram but without identifiable feeder vessels, and the number of patients with vision loss, from baseline, of 15 letters or more, 30 letters or more, or are reduced to less than 5 letters read. All adverse events regardless of severity or relatedness to the therapy will be collected and summarized. Assessment of all outcomes will be made at 6 weeks, 3, 6, 12, 18, and 24 months post laser treatment, and 24 months after enrollment. This study will give investigators some insight into this technology and the feasibility of this treatment in patients with various forms of neovascular AMD. In addition, the results of the study will provide the foundation for larger studies of this therapy.


- INCLUSION CRITERIA: 1. To participate in this study, the patient must understand and sign the protocol informed consent. 2. Age greater than or equal to 50 years. 3. In at least one eye, diagnosis of AMD defined by the presence of drusen larger than 63 microm and the presence of choroidal neovascularization under the fovea determined by the Principal Investigator and defined as any one of the following fluorescein angiographic features: 1. Early stippled hyperfluorescence of flat retinal pigment epithelium with ill-defined boundary and little or mild leakage in the late frames of the fluorescein. 2. Irregular elevation of the retinal pigment epithelium that does not exhibit discrete or bright hyperfluorescence in the early transit phase of the angiogram. Stippled hyperfluorescence may be present. Late frames may show persistent fluorescein staining or leakage within a sensory retinal detachment overlying this area. 3. Early well-defined lacy hyperfluorescence with late frames that show persistent fluorescein staining or leakage. 4. Early filling of fluorescein beneath the retinal pigment epithelium with progressive filling during the study and persistent leakage/staining of the space. This may be associated with a "notch" at the borders, areas of more localized leakage at the edge or irregular filling of the area with discrete areas of blockage. 5. Early hyperfluorescence with late frames that shown progressive staining and leakage into surrounding tissue. The eligible eye will be considered the study eye. If both eyes are eligible, the eye with the worse visual acuity will be considered the study eye. 4. Patient must have at least one potential feeder vessels in the study eye identified using Phi-motion ICG. 5. First 5 patients: visual acuity of 20/200 or worse in the study eye. Remaining 15 patients: visual acuity of 20/50 or worse in the study eye. 6. The fellow eye must have visual acuity the same or better than the study eye. 7. Ineligible for a clinically proven laser photocoagulation or photodynamic therapy protocols. 8. Retinal photographs and angiography of sufficient quality allowing assessment of the macular area according to standard clinical practice can be obtained. EXCLUSION CRITERIA: 1. Choroidal neovascularization, in the study eye, associated with other ocular diseases such as pathologic myopia, ocular histoplasmosis or posterior uveitis, etc. 2. Presence of geographic atrophy under the fovea in the study eye. 3. Decreased vision, in the study eye, due to retinal disease not attributable to CNVM, such as nonexudative forms of ARM, geographic atrophy, inherited retinal dystrophy, uveitis or epiretinal membrane. 4. Decreased vision, in the study eye, due to significant media opacity such as corneal disease or cataract, or opacity precluding photography of the retina. 5. History of other antiangiogenic treatment with thalidomide or alpha interferon. 6. Any contraindications to performing the necessary diagnostic studies, especially the use of fluorescein or indocyanine green angiography. 7. Allergy to shellfish, iodine or previous iodine containing dyes. 8. Medical problems that make consistent follow-up over the treatment period unlikely (e.g. stroke, severe MI, terminal carcinoma). 9. Current use of or likely need for systemic or ocular medications known to be toxic to the lens, retina or optic nerve, such as: 1. Deferoxamine 2. Chloroquine/Hydroxychloroquine (Plaquenil) 3. Tamoxifen 4. Phenothiazine 5. Phenothiazines 6. Ethambutol 10. Well-defined choroidal neovascularization (as defined by the MPS) whose area, as seen on the early frames of the SFA, is greater than 50% of the total area of late leakage or staining as determined by the Principal Investigator. 11. Concomitant administration of other experimental therapies for AMD.



Primary Contact:


Backup Contact:


Location Contact:

Bethesda, Maryland 20892
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.